ALS: Blocking inflammation to reduce symptoms

ALS is caused by the loss of upper motor neurons, located in the brain, and lower motor neurons, which extend from the spinal cord to the muscles. Using a genetically modified mouse model, Chantelle Sephton and her team found that structural changes in the upper neurons occurred prior to disease symptoms.

The study suggests that these morphological changes send a signal to microglia and astrocytes, the immune cells of the central nervous system. When they arrive, their effect is protective, but if they stay too long, they become toxic to neurons. This leads to a reduction in synaptic connections between motor neurons in the brain and spinal cord, which in turn results in a reduction in synaptic connections with muscles. These changes lead to atrophy and loss of motor function.

Given this correlation between symptoms and immune response, the research team wondered whether it might be possible to restore synaptic connections by blocking inflammation. " We tested a semi-synthetic drug based on Withaferin A, an extract of the Ashwagandha plant, which has been used for thousands of years in traditional Indian medicine," explains CERVO Research Center affiliate Chantelle Sephton.

The drug blocks inflammation and allows motor neurons to return to a more normal state. "We have noticed that neurons regenerate in the absence of activated immune cells. The dendrites of motor neurons start to grow and make connections again, increasing the number of synapses between motor neurons and muscles," reports the researcher.

This seems a promising way of improving ALS symptoms, whether the disease is familial or sporadic, since both types are associated with inflammation.

Other diseases where inflammation plays a role, such as Alzheimer's, could benefit from this approach.

The study was published in the scientific journal Acta Neuropathologica Communications. The signatories are Mari Carmen Pelaez, Antoine Desmeules, Pauline Gelon, Bastien Glasson, Laetitia Marcadet, Alicia Rodgers, Daniel Phaneuf, Silvia Pozzi, Paul Dutchak, Jean-Pierre Julien and Chantelle Sephton.